TCR2 Therapeutics Inc logo

TCR2 Therapeutics Inc

$ 1.44 +0.11 (+8.27%) 08:08 PM EST
P/E:
At Loss
P/B:
0.28
Market Cap:
$ 55.67M
Enterprise V:
$ -66.34M
Volume:
482.35K
Avg Vol (2M):
212.09K
Also Trade In:
Volume:
482.35K
Market Cap $:
55.67M
PE Ratio:
At Loss
Avg Vol (2-Month):
212.09K
Enterprise Value $:
-66.34M
PB Ratio:
0.28
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which is effective in patients with solid tumors.
Name Current Vs Industry Vs History
Cash-To-Debt 3.02
Equity-to-Asset 0.73
Debt-to-Equity 0.29
Debt-to-EBITDA -0.5
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -31.5
3-Year EPS without NRI Growth Rate 0.3
3-Year FCF Growth Rate -42.3
Name Current Vs Industry Vs History
5-Day RSI 58.85
9-Day RSI 47.35
14-Day RSI 40.67
6-1 Month Momentum % -32.3
12-1 Month Momentum % -69.52

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.02
Quick Ratio 5.02
Cash Ratio 4.8

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -18.4
Name Current Vs Industry Vs History
ROE % -46.95
ROA % -37.81
ROIC % -137.16
ROC (Joel Greenblatt) % -176.53
ROCE % -41.76

Financials (Next Earnings Date:2023-03-22 Est.)

TCRR's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Gurus Latest Trades with NAS:TCRR

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -3.09
Beta 1.91
Volatility % 60.04
14-Day RSI 40.67
14-Day ATR ($) 0.089071
20-Day SMA ($) 1.3435
12-1 Month Momentum % -69.52
52-Week Range ($) 1.23 - 5.51
Shares Outstanding (Mil) 38.66

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

TCR2 Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

TCR2 Therapeutics Inc Analysis

Share your research

Headlines

See More
No news.